1. Supplementary materials
MiR-145 Improves Macrophage-Mediated Inflammation Through Targeting Arf6

2. Supplementary table 1-1: Comparison sequences of pYr-MirTarget-arf6-3’UTR plasmid .
Sequence 0: part of sequences for Arf6 3’URT from NCBI
Sequence 1: sequences of pYr-MirTarget-arf6-3’UTR plasmid

3. Supplementary table 1-2: Comparison sequences of mutated Arf6 plasmid .
Sequence 0: part of sequences for Arf6 3’URT from NCBI
Sequence 1: sequences of mutated Arf6 plasmid, CTGG were mutated into GACC,
Predicted binding sequences were AACTGGA at these two white sides.

4. laparoscopic cholecystectomy
Supplementary table 2: General characteristics of patients who provided adipose tissue during surgery
number
gender
age(yr)
diabetes
height(cm)
weitht(kg)
BMI(kg/m2) a
SBP(mmHg) b
DBP(mmHg) c
FPG(mmol/l) d
2hPG(mmol/l) e
HbA1c(%)
groupf
Reason for surgery
L0032
female 35 /g
164 55
20.45 92 60
4.5 / 5 1
laparoscopic cholecystectomy
L0039 49
150
24.44
120 80
5.2
5.6
L0042 46
168 57
20.20
113 72
5.3
L0050
male 52
170 65
22.49 98 70
4.3
L0056 47
166
23.59
130 76
5.8
9.2
6.2
gastric stromal tumor
L0059 44 67
23.74
L0062 53
180
22.22
132 90
inguinal hernia
F0078 21
161
101
38.96 75
5.70 2
bariatric surgery
F0081 28
94.5
33.48
4.6
6.7
5.00
F0087 31
183
127.5
38.07
5.1
7.9
5.80
F0111
175
140
45.71
133 87
6.10
F0114 36 88
31.18
142 82
5.7
8.9
5.30
F0117 25
165
31.96
5.9
5.40
F0123 22 96
34.01
117
4.2
4.1
5.20
F0041 30
Y h
187
151
43.18
148 86
10.4
18.8
9.3 3
F0052 Y
147
48.00 94
12.2
16.5
7.1
F0066 50
172
43.94
123 91
8.4
14.6
7.2
F0085
100
35.43
155
109
7.4
14.8
7.60
F0092 33 97
35.63
126 16
22.4
11.00
F0110 41
159
105
41.53
12.9
20.6
10.70
F0121
185
38.57
136
11.10
BMI: body mass index; b. SBP: systolic blood pressure; c. DBP: diastolic blood pressure; d. FPG: fasting plasma glucose; e. 2hPG: 2-hour plasma glucose. f. Group1 as control group (n=7) means those who were not obese without diabetes. Group 2 is Obesity group(n=7) which means those who were obese without diabetes. Group 3 is Obesity+DM group(n=7) meaning those who were obese with diabetes. g. / means without self-reported information or test results; h. Y means yes, with history of diabetes.

5. a. BMI: body mass index; b. SBP: systolic blood pressure; c
a. BMI: body mass index; b. SBP: systolic blood pressure; c. DBP: diastolic blood pressure; d. FPG: fasting plasma glucose; e. 2hPG: 2-hour plasma glucose. f. Group1 as control group (n=7) means those who were not obese without diabetes. Group 2 is Obesity group(n=7) which means those who were obese without diabetes. Group 3 is Obesity+DM group(n=7) meaning those who were obese with diabetes. g. / means without self-reported information or test results; h. Y means yes, with history of diabetes.

6. Supplementary table 3: Primers sequences lists.
name
species
sequences
Arf6
Human
Forward 5’-CCATGAAACCCCACGAGA-3’
Reverse 5’-AGGGCTGCACATACCAGTTC-3’
TNF-alpha
Forward 5’- CAGCCTCTTCTCCTTCCTGAT-3’
Reverse 5’- GCCAGAGGGCTGATTAGAGA-3’
IL-1beta
Forward 5’- TACCTGTCCTGCGTGTTGAA-3’
Reverse 5’- TCTTTGGGTAATTTTTGGGATCT-3’
MCP-1
Forward 5’- CTCAGCCAGATGCAATCAAT-3’
Reverse 5’- AGCTTCTTTGGGACACTTGC-3’
IL-6
Forward 5’- GCCACTCACCTCTTCAGAACG -3’
Reverse 5’- CAGTGCCTCTTTGCTGCTTTC -3’
IL-10
Forward 5’- GACCACGCTTTCTAGCTGTTG -3’
Reverse 5’- GCTCCCTGGTTTCTCTTCCT -3’
beta-actin
Forward 5’- CTGGCTGGCCGGGACCTGACA -3’
Reverse 5’- ACCGCTCGTTGCCAATAGTGATGA -3’
GAPDH
B661104, Sangon Biotech, China U6
MPH00001, Applied Biological Materials, Canada
miR-145-5p
MPH02201, Applied Biological Materials, Canada
Universal 3’miRNA
Universal
MPH00000, Applied Biological Materials, Canada

7. Supplementary figure 1: The mRNA expression of MCP-1, IL-10, and IL-6/IL-10 in miR145 inhibitor transfection
miR-145-
The mRNA expression of cytokines MCP-1, IL-10, and IL-6/IL-10 in THP-1 cells was determined by qRT-PCR.
*p<0.05, **p<0.01, ****p< compared with NC inhibitor, respectively.

8. *p<0.05, ****p<0.0001 compared with NC mimic, respectively.
Supplementary figure 2: The mRNA expression of IL-1beta, IL-10, and IL-6/IL-10 in miR145 mimic transfection
miR-145+
The mRNA expression of cytokines IL-1beta, IL-10, and IL-6/IL-10 in THP-1 cells was determined by qRT-PCR.
*p<0.05, ****p< compared with NC mimic, respectively.

9. *p<0.05, **p<0.01, compared with negative control, respectively.
Supplementary figure 3: The mRNA expression of IL-10, and IL-6/IL-10 in LV-ARF6-RNAi transfection
LV-ARF6-RNAi
The mRNA expression of cytokines IL-10, and IL-6/IL-10 in THP-1 cells was determined by qRT-PCR.
*p<0.05, **p<0.01, compared with negative control, respectively.

10. of obese patients and diabetics.
Supplementary figure 4: The mRNA expression of IL-10, and Il-6/IL-10 in omental adipose tissue
of obese patients and diabetics.
Human adipose tissue
The mRNA expression of cytokines IL-10, and IL-6/IL-10 in omental adipose was determined by qRT-PCR.
*p<0.05, ***p<0.001 compared with control group.